Abstract
The model systems available for studying human hematopoiesis, malignant hematopoiesis and hematopoietic stem cell (HSC) function in vivo have improved dramatically over the past decade, primarily due to improvements in xenograft mouse strains. Several recent reviews have focused on the historic development of immunodeficient mice over the past two decades as well as their use in understanding human HSC and leukemia stem cell (LSC) biology and function in the context of a humanized mouse. However, in the intervening time since these reviews, a number of new mouse models, technical approaches and scientific advances have been made. In this review, we update the reader on the newest and best models and approaches available for studying human malignant and normal hematopoietic stem cells in immunodeficient mice, including newly developed mice for use in chemotherapy testing as well as improved techniques for humanizing mice without laborious purification of HSC. We also review some relevant scientific findings from xenograft studies and highlight the continued limitations that confront researchers working with human HSC and LSC in vivo.
Immunodeficient mice for studying normal and malignant human hematopoiesis
Since immunodeficient mice were first used in biomedical research, there has been a continual effort to improve their utility and expand their applicability to more areas of research. Over the past decade, with the advent of widespread transgenic approaches and the understanding by researchers of the potential for these models in moving our understanding of biology forward, a number of genetically engineered animals have become available. For a comprehensive overview of the history and use of xenografting, the reader is directed to a number of recent reviews [1] [2] [3] [4] [5] . In this review we will focus on the models and approaches of most relevance to researchers studying normal and malignant hematopoiesis and discuss future avenues to take that will address current limitations.
Of the different strains available to the research community, the most popular strains are the NOD/SCID-IL2RG /Jic : NOG) mice 6, 7 . Variations of this strain are becoming available through breeding strategies and genomic engineering techniques. It is clear that different strains will be optimal for different types of studies. For example, the humanized mouse, in which components of human bone marrow (BM), liver, and thymus (BLT) are grafted in immunodeficient mice, is most popular with investigators studying infectious disease due to the faithful development of mature, properly educated human T cells and a more complete, functional human immune system 5, 8 . The BLT approach is powerful but requires specialized surgical expertise and additional time, as well as tissue from human fetuses, raising feasibility issues. For studying hematologic malignancies, many researchers use the NSG mouse expressing cytokines that support human myelopoiesis (NSG-hSCF, hGM-CSF, hIL3, all driven from CMV promoter; NSGS), for their superiority in promoting robust engraftment of a wide range of patient samples 9, 10 . Designer mice are now becoming available through the efforts of a number of labs around the world, with Drs. Mamoru Ito (NOG), Leonard Shultz (NSG), and Richard Flavell and Markus Manz (Rag2 -/-IL2RG -/-) leading the way on improvements in these mouse strains. In a relatively short period of time, numerous genetically modified sub-strains will be available that seek to address the cross-species incompatibility of growth factors, receptors, adhesion molecules and histocompatibility antigens. Engraftment levels in these three mouse strains are relatively equal now that the Rag2 -/-
IL2RG
-/-mice express the human SIRPα molecule 11, 12 (Figure 1 ).
Xenograft Models for Analysis of human Hematopoietic Stem Cells
For studies focused on human HSC self-renewal in vivo, the NSG/NOG mice are preferred due to their widespread availability and excellent engraftment rate. Although high levels of sustained engraftment can be obtained upon transplant of human CD34+ cells into primary mice, secondary transplants are rarely performed, and for those reported, most show low levels of engrafted human cells. In one study, the authors demonstrated that the primitive stem/progenitor cells remain in active cycle for up to 8 weeks post-engraftment, possibly implicating a lack of quiescence as the driving factor in the limited self-renewal 13 . This could also explain the unusually high frequency of human CD34+ cells detected in the BM of xenografted mice (10-20% of the human graft) when compared with a normal human BM containing 1-2% CD34+ cells at steady state 14, 15 . It is possible the signals that normally induce transplanted HSC to enter quiescence are absent and/or non-cross-reactive in the immunodeficient mouse. To address this, Flavell's group used Rag2 -/-IL2RG -/-mice expressing human TPO in place of murine. However only a slight enhancement in serial transplantation was observed 16 . It is likely that multiple signals are aberrant in the murine microenvironment and a complex array of genetic changes will be needed to mimic the human BM niche. It is also possible that the presence of facilitating cells during transplant is critical for proper function of the HSC. We recently described a simple procedure using total BM or cord blood samples in xenotransplants. The addition of the OKT3 monoclonal antibody to a cell mixture readily addressed the graft versus host disease that ensues upon transplanting samples containing mature T cells into immunodeficient mice. This process also more closely mimics the stem cell transplant procedure as it is performed in humans 17 . Limiting dilution analysis showed the stem cell frequency was as good or better than approaches using purified human CD34+ cells. Secondary transplant was very robust in a small pilot experiment, ranging between 10 and 50% multi-lineage human engraftment in the BM at 16 weeks, dramatically better than found in most published studies. More work is needed to determine whether this approach will contribute to solving the problems associated with analysis of human HSC self-renewal in xenotransplants.
Unfortunately, there is currently no standard in the field regarding which mice, approaches and time-points are best for measuring human HSC activity in vivo. A wide range of engraftment levels and durations have been used as experimental endpoints, and few researchers use secondary transplant as a readout due to poor engraftment. It is important that researchers adopt an accepted standard for measuring human HSC and HSPC function as has been done for murine HSPC studies. This will allow a straightforward comparison of different approaches and models using a standard methodology.
Biology of human Hematopoietic Stem Cells
Xenograft models have been used to determine immunophenotypes of human HSCs. In contrast to murine HSCs that are enriched in the CD34-negative fraction, CD34 has long been used as a positive marker of human HSCs not only in xenograft repopulation assays but also in clinical HSC transplantation 18, 19 . Additional HSC markers have been identified, and it is now possible to isolate human HSCs at the single cell level [20] [21] [22] [23] [24] [25] [26] [27] [28] . Some primitive human HSCs may reside in a CD34-negative fraction similar to murine HSCs, but the frequency of CD34-negative SCIDrepopulating cells (SRCs) is very low even with the use of additional HSC markers [29] [30] [31] (Table 1 ). Interestingly, current evidence suggests that human HSCs have little correspondence with murine HSCs in terms of surface marker expression. Stem cell antigen-1 (Sca-1) is used extensively to enrich for murine HSCs, but it does not have a human homolog 32 . Human HSCs express FLT3, while mouse HSCs do not 33 . CD38 is not expressed on human HSCs, but is expressed on murine HSCs [34] [35] [36] . CD150, a member of the SLAM family receptors, has been widely used to isolate murine HSCs 37 . However, human HSCs cannot be purified based only on SLAM markers 38 . In addition, human HSCs expressing high levels of KIT (KIT-hi) contain more potent repopulating activity compared to HSCs expressing intermediate levels ( KIT-int) 39 , while Kit-int murine HSCs are the best at repopulation and Kithi defines murine HSCs initiating the process of differentiation 40 . These discrepancies likely indicate species differences, but may partially be explained by different experimental conditions (syngeneic transplantation vs xenotransplantation). It should also be noted that many previous xenograft studies assessed engraftment of human HSCs at a relatively early timepoint (6-12 weeks post-transplant, Table 1 ). Given that long-term HSCs show a delayed engraftment pattern 41 , a longer period (or serial transplant) may be needed in future studies.
Studies for ex vivo HSC expansion combined with xenograft assays have revealed mechanisms governing selfrenewal of human HSCs. Many studies have suggested that Notch signaling plays important roles in the regulation of human HSCs. Activation of Notch receptors by ligands (JAG1, DLL1, or DLL4) has been shown to promote ex vivo expansion of SRCs [42] [43] [44] [45] . In line with this, enforced expressions of HES1 (a Notch target gene) and NOV (an extracellular activator of Notch signaling) in human CB cells confer enhanced in vivo reconstitution ability in NOD/SCID mice 46, 47 . Notch signaling may also regulate the quiescent state of CD34-HSCs together with TGFβ to repress the Wnt pathway 30 . The effect of Notch on human HSCs appears to be dosage-dependent, since low doses of DLL1 expands CD34 + cells while higher doses induce apoptosis 48 . Early studies also identified WNT and hedgehog pathways to promote HSC expansion [49] [50] [51] , and several inhibitory pathways, including TGFߚ, TNFα, and chemokines, to suppress HSC proliferation (reviewed in 52 ). Recent studies have identified new pathways involved in human HSC regulation. Angptl5, a member of Angiopoietin-like proteins, promotes 20-fold expansion of SRCs when used in serum-free culture media containing SCF, TPO, FGF1, and IGFBP2 53 . A neurite outgrowth factor Pleiotrophin also increases SRC counts in culture, and Notch and PI3k pathways mediate the response to Pleiotrophin 54 . A zebrafish screen and subsequent reports have shown that Prostaglandin E2 (PGE2) enhances emergence and repopulating ability of HSCs through activation of WNT signaling and upregulation of CXCR4 and Survivin [55] [56] [57] [58] . Conversely, inhibition of endogenous PGE2 by nonsteroidal anti-inflammatory drug treatment promotes HSC egress from the BM to the circulating blood not only in mice but also in healthy human volunteers 59 . More recently, an unbiased drug screening identified an aryl hydrocarbon receptor (AhR) antagonist SR1 that promotes ex vivo expansion of human CD34+ cells that retain the ability to engraft NSG mice 60 . AhR requires ARNT (HIF1B) to regulate gene expression, and interestingly, ARNT is also required by HIF1A to enhance gene expression in response to hypoxia 61 , suggesting the involvement of the HIF pathway in the regulation of human HSCs. Indeed, a study showed that knockdown of HIF2A, and to a lesser extent HIF1A, impedes the long-term repopulating ability of human CB CD34+ cells through increased reactive oxygen species (ROS) production and endoplasmic reticulum stress 62 . In addition, treatment of recipient mice with the ROS scavenger N-acetyl-Lcysteine (NAC) significantly improves engraftment of human HSC in NOD/SCID and NSG mice 63 . Another recent screening confirmed that multiple compounds suppressing the AhR pathway can promote HSC expansion ex vivo, although it appears that SR1 mainly expands short-term HSCs with limited regenerative potential. Interestingly, the study also identified a compound UM171 that efficiently promotes a robust ex vivo expansion of long-term human HSCs through AhR-independent mechanisms 64 . As for the inhibitory signaling for human HSCs, shRNA library screening identified MAPK14 (p38α) as a negative HSC regulator. Pharmacologic inhibition of p38 dramatically enhances the multilineage repopulation of human CB cells in NSG mice presumably by reducing levels of ROS 65 .
Several transcription factors possess the ability to promote HSC expansion ex vivo. HOX proteins, HOXB4 and HOXC4, moderately (2-6 fold) improve the level of in vivo engraftment of human CD34+ cells 66, 67 . Similarly, enforced HLF expression confers increased repopulation potential to human HSCs 46 . RUNX1 has isoform-specific activity to regulate self-renewal and differentiation of HSCs. Forced expression of RUNX1a, a short isoform of RUNX1, increases SRC activity of human HSCs and facilitates emergence of definitive human HSCs from human embryonic stem cells 68, 69 . In contrast, long isoforms of RUNX1 (RUNX1b and RUNX1c) inhibit repopulation of human/mouse HSCs in recipient mice by promoting myeloid differentiation 68, 70 and/or increasing quiescence of HSCs 71 . GATA2 is highly expressed in quiescent HSC fractions, and enforcing GATA2 expression increases quiescence of human CB cells 72 . DNA damage response is essential for maintaining HSC function, and p53 plays a key role in this process. In contrast to mouse HSCs with decreased sensitivity to cytotoxic agents, human HSCs exhibit enhanced p53-dependent apoptosis after irradiation. Inactivation of p53 reduces apoptosis and partially rescues the repopulating ability of the irradiated HSCs in primary recipient mice. However, p53-depleted HSCs show diminished SRC activity in secondary recipients probably due to accumulated DNA damage, suggesting that intact p53 is important to maintain human HSCs in the serial transplantation assay 73 . In addition to these transcription factors, epigenetic modifiers also regulate human HSC function. The polycomb complex protein BMI1 was shown to promote the repopulation potential of human HSCs 74, 75 . Furthermore, addition of epigenetic drugs can increase the self-renewal of human HSCs ex vivo. Human CB cells treated with decitabine (DNA methylation inhibitor) and trichostatin A (histone deacetylase inhibitor: HDACi) in the presence of hematopoietic cytokines resulted in significant expansion of CD34+CD90+ cells, including transplantable HSCs 76, 77 . Another HDACi valproic acid also stimulated proliferation and self-renewal of human HSCs accompanied by p21 cip1/waf1 downregulation, WNT pathway activation, and HOXB4 upregulation 78 . Finally, increasing evidence suggests the importance of miRNAs for human HSC regulation (reviewed in 79, 80 ). Among the miRNAs highly expressed in human HSCs, miR-125 was shown to regulate HSC function positively 81 , while miR-126 was shown to be a negative regulator of HSC proliferation 82 .
Although these studies have revealed key players to maintain/expand human HSCs (Figure 2 ), it should be noted that signals needed for HSC expansion ex vivo may be different from those to maintain HSCs in human bodies. Indeed, a recent study showed that Notch signaling might be dispensable for self-renewal of human HSCs in vivo. Inhibition of Notch activity using a dominant-negative inhibitor of Mastermind-like (dnMAML) did not change SRCs when the dnMAML-transduced HSCs were directly transplanted to NSG mice, whereas dnMAMLtransduced HSCs were not maintained ex vivo 83 . Developing more "humanized" mice will be necessary to decipher actual mechanisms regulating human HSCs in vivo.
renewal divisions in the absence of the normal niche signals needed by HSC. These differences may also reflect discrepancies in the intrinsic nature of leukemia versus normal stem cells such that LSC do not exhaust their selfrenewal ability when mobilized into cycle while HSC do (Figure 3 ).
Although transfer of leukemia samples to immune deficient hosts has greatly improved, a substantial number of samples still fail to engraft even the most optimized host mice 9, 86 . Together, these data indicate that significant interspecies barriers to engraftment and expansion of certain LSCs remain, particularly for less aggressive hematologic malignancies. Specific subtypes of leukemia are significantly more problematic to engraft, for example, samples from patients with t(8;21). It may be that some subtypes of AML have low progenitor cell frequency, or, some samples may be particularly sensitive to the lack of a factor or cell type from the mouse BM. In the case of t(8;21), we and others have shown that signaling through TPO/mpl is particularly important for the growth of cells expressing AML1-ETO 87, 88 . Thus, hTPO knockin mice may improve engraftment of t(8;21) AML, as appears to be the case according to a presentation at the 2014 American Society of Hematology annual meeting 16, 89, 90 . It should also be noted that "engraftment" itself does not indicate the detection of LSCs because residual normal HSCs in patients can repopulate mice. It is therefore important to confirm genetic and phenotypic abnormalities of the engrafted human cells in studies for human LSC. Interestingly, a recent xenograft study demonstrated the existence of "preleukemic" HSCs with a DNMT3A mutation. The preleukemic HSCs did not show leukemic engraftment characterized by a dominant myeloid graft, but showed a multilineage repopulation advantage over non-mutated HSCs 91 . Xenograft models combined with genetic analyses will enable the identification of preleukemic and leukemic stem cells in patients.
There is a growing list of studies that examine the effects of individual leukemia-associated oncogenes on human hematopoietic stem and progenitor cells (HSPC), in effect "building" human leukemia using primary human HSPC (Table 2 ). While most of these studies report only partial phenotypes, consistent with a model of stepwise progression to transformation, there are now several examples of ex vivo generation of human leukemia from primary human cells as assayed by xenografts using defined genetic elements [92] [93] [94] [95] . These successes are limited to a select few recurrent translocations, likely indicating that most oncogenes require cooperating genetic mutations to elicit full-blown transformation. These studies also reiterate the finding that human cells are more refractory to transformation than are murine cells, as shown experimentally 96 . It is also likely that BM microenvironmental cues are critical for pre-leukemic HSPC initiation and leukemia progression, similar to the situation for normal human HSC, in contrast to a fully transformed LSC.
Whether xenograft models can be used to predict response to leukemia therapy is an open question. Early studies showed a correlation between engraftment of AML samples in NOD/SCID mice and poor clinical outcome, and this finding has been replicated in NSG mice 97, 98 . However, whether the phenotypically defined LSC frequency (simplistically characterized as CD34+CD38-) in AML is prognostic and whether this correlates with xenograft potential is controversial 98-100 . Interestingly, it was shown that poor clinical outcome correlated with the degree to which the LSCs matched normal HSC gene expression 101 . Whether this means that the transformative event(s) occurs initially in true HSCs or rather it results from transformed progenitors acquiring stem cell activity and gene expression remains unclear. More work remains to be done before strong conclusions can be drawn, but it may be possible to use data derived from xenografted AML samples to identify biomarkers that may predict clinical outcome.
Xenograft models also provide powerful tools to perform preclinical testing of candidate drugs for hematological malignancies. However, we should keep it in mind that the dominant clone present at relapse in a patient is not necessarily the clone emerging upon xenotransplantation 102 . This may be due to different selective pressures in xenotransplant relative to what the AML clones encounter in patients undergoing induction and consolidation therapy. Xenomodels combined with therapeutic treatments may better mimic the situation of patients. We have recently shown that NSGS mice can be used to mimic induction therapy during xenograft 103 . One drawback to this approach is the frailty of SCID-based mice, making it impossible to simultaneously use conditioning to ensure engraftment of AML samples and subsequently treating with induction chemotherapy to force outgrowth of a relapse clone. We have crossed the NSGS mice with the NRG mice and found these mice (NRGS) are robust enough to permit conditioning, induction, intensified induction and consolidation without death of the host (unpublished observations). This is consistent with the demonstration of radioresistance of the NRG strain 104 . We expect the NRGS host combined with drug treatments will allow an examination of clonal evolution in leukemia under similar pressure to that in patients receiving therapies. These mice will be commercially available in 2015.
Biology of human Leukemia Stem Cells
Xenograft studies have identified many useful markers to enrich LSCs, but it has become increasingly evident that LSC phenotype varies between individual patients. In addition, technical variation of xenograft assays also affects the results, with a trend that more immunodeficient strains allow the engraftment of variable LSC populations 10, 84, 101, (Table 3) . Early pioneering studies using NOD/SCID mice showed that AML is a hierarchical disease that is initiated by a rare subset of immature CD34+CD38-LSCs 84 . However, LSCs were found in other compartments including the CD34+CD38+ fraction in recent studies using NSG mice or NOD/SCID mice treated with anti-CD122 to inhibit NK cell function 101, 109, 114 . Furthermore, AMLs with NPM1 mutations were shown to contain LSCs in the CD34-fraction 110 , indicating the subtype-specific features of AML LSC. Although human LSC and HSC share similar immunophenotypes, some markers such as CD123 (IL3-R ), CD96, CD44, CD47, CD32, CD25, CLL-1, IL1RAP and TIM3 appear to be expressed higher in LSCs than normal HSCs, providing potential therapeutic targets to selectively eradicate LSCs 105, 107, 108, 111, 112, [127] [128] [129] [130] [131] [132] Hierarchical organization is less strict in acute lymphoid leukemia (ALL). Some early studies showed the exclusive engraftment of primitive ALL LSCs (CD34+CD19-/CD10-for B-ALL and CD34+CD4-/CD7-for T-ALL) in NOD/SCID mice 117, 118, 122 , but many later studies demonstrated LSC potential of cells with phenotypic characteristics of differentiated progenitors (CD19+ cells for B-ALL and CD7+ cells for T-ALL) [119] [120] [121] 123 . Interestingly, a recent study suggests that chronic lymphocytic leukemia (CLL) may be derived from primitive HSPC. Purified HSCs from CLL patients could initiate xenografts that gave clonal expansion of B cells, while other isolated fractions did not have this ability 124 . Interestingly, leukemic clones derived from the same patient but expanded in different mice exhibited distinct VDJ recombination events, clearly suggesting a primitive preleukemic stem cell is driving a disease that continues to evolve in the xenografted mice. As immunodeficient models and techniques improve, more such studies will be possible using primary patient samples from a variety of hematologic malignancies.
Future Improvements in Xenograft Models
Advances in the available mouse strains and in the techniques used to humanize the murine immune system and to model human hematologic malignancies in vivo have been dramatic over the past few years. Numerous important findings have been made with regard to the nature and function of human HSC and LSC. Nevertheless, some major hurdles remain to be overcome to broaden the use of this approach to studying the human LT-HSC and to model hematologic malignancies that are not currently amenable to xenograft.
The arm of the immune system that has proven most difficult to model in immunodeficient mice is the megakaryocytic and erythrocytic lineages. Numerous reasons have been proposed for the problems associated with development of these lineages, and it is likely that the problems are multi-faceted and will not be solved with a single genetic "fix" 4 . Phagocytosis of red blood cells and platelets by murine macrophages has been shown to play a role in the lack of these cell types in the periphery of humanized mice 138, 139 . However, humanized mice also have a dramatic defect in the generation of the megakaryocytic/erythroid progenitor (MEP) and this deficiency is not corrected in Rag2 -/-IL2RG -/-mice expressing human thrombopoietin 16 . The lack of human megakaryocytes in the BM of humanized mice could play a role in the quiescence and self-renewal problems of the human HSC given the recent findings that mature megakaryocytes are essential niche cells for HSC 140, 141 . One possible contributing factor to both the HSC and MEP defects is the increased ROS levels found in NS and NSG mice 142 . ROS levels have been shown to be particularly low in MEP, and low levels of ROS in the common myeloid progenitor correlate with gene expression signatures that favor the MEP fate 143 . It is possible that correction of the high ROS levels in these immunodeficient mice may allow for development of a more complete immune system and simultaneously promote the quiescence and self-renewal of the human HSC through multiple mechanisms.
The development of genetically modified immunodeficient mice will continue, likely at an increased pace. These modifications will include not only substitutions of growth factors, receptors and adhesion molecules but also major histocompatibility molecules to promote proper education and development of cells dependent on these molecules for function. In the near future it is likely that an improved xenograft mouse will be available for most blood researchers, including specialists focused on human HSC and LSC. The in vivo approaches that are critical to a better understanding of stem cell function will be even more powerful than the excellent models that currently exist. In time, our scientific understanding of human stem cell function will rival that of the murine stem cell.
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C a n c e r C e l l . For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Figure legends Discovery of nude and SCID mice, in which T cells or T/B cells are deficient, contributed to the early phase development of xenograft models. NOD/SCID mice, which harbor defects in T, B, and macrophage activity, supported higher levels of human engraftment and promoted the further development of xenomodels. Currently, mice with almost no murine immunity, such as NOG and NSG mice, are widely in xenograft studies. Variations of these strains including BLT model and human cytokine mice are becoming available to provide optimal xenomodels for specific studies. Mouse hematopoietic stem cells (HSCs) interact with the niche, which promotes quiescence. Several observations suggest that the mouse niche does not support human HSCs to maintain quiescence and stemness. As a result, human HSCs are proliferative in xenograft models, which leads to HSC differentiation. Human leukemia stem cells (LSCs) from aggressive types of leukemia do not appear to require the support from the mouse niche to maintain leukemic growth. 
